Serial No.: 10/540341 Docket No : X-15463

## Amendments to the Claims

## In the Claims

This listing of claims will replace all prior versions and listings of claims in the application. Amendments to the claims are without prejudice.

## What is claimed is:

- 1. (Canceled)
- 2. (Canceled)
- 3. (Canceled)
- 4. (Canceled)
- 5. (Canceled)
- 6. (Canceled)
- 7. (Canceled)
- 8. (Canceled)
- 9.
- (Canceled)

10.

11.

(Canceled)

(Canceled)

- 12. (Canceled)
- 13. (Canceled)
- 14. (Canceled)
- 15. (Canceled)
- 16. (Canceled)
- 17. (Canceled)
- 18. (Canceled)
- 19. (Canceled)
- 20. (Canceled)
- 21. (Canceled)
- 22. (Canceled)
- 23. (Canceled)
- 24. (Canceled)
- 25. (Canceled)
- 26. (Canceled)
- 27. (Canceled)

Serial No.: 10/540341 Docket No.: X-15463

- 28. (Canceled)
- 29. (Canceled)
- 30. (Canceled)
- 31. (Canceled)
- 32. (Canceled)
- (Canceled)
- 34. (Canceled)
- 35. (Canceled)
- 36. (Canceled)
- 37. (Canceled)
- 38. (Canceled)
- 39. (Canceled)
- 40. (Canceled)
- (-----
- 41. (Canceled)
- 42. (Canceled)
- 43. (Canceled)
- (Currently Amended) A compound as claimed by Claim 18 represented by the following Structural Formula III:

or a pharmaceutically

acceptable salt thereof, wherein R33 is selected from the group consisting of hydrogen and C<sub>1</sub>-C<sub>3</sub> alkyl; X is a single bond; Y is a single bond; E is – CH2COOH; R1 is H; R8 is H or C<sub>1</sub>-C<sub>4</sub> alkyl; R9 is H or C<sub>1</sub>-C<sub>4</sub> alkyl; R10 is CF3; R11 is H; R32 is H, C1-C6alkyl, or C1-C6alkyloxo; U is an aliphatic linker replaced with an O.

- 45. (Canceled)
- 46. (Canceled)
- 47. (Canceled)
- 48. (Canceeld)
- 49. (Canceled)
- 50. (Canceled)

Serial No.: 10/540341 Docket No.: X-15463

- 51. (Canceled)
- 52. (Canceled)
- 53. (Canceled)
- (Currently amended) A pharmaceutical composition, comprising as an active ingredient, at least one compound as claimed by-Claim 18 Claim 44, together with a pharmaceutically acceptable carrier or diluent.
- 55. (Canceled)
- (Currently Amended) A method of treating diabetes mellitus in a mammal, comprising the step of administering to the mammal in need thereof a therapeutically effective amount of at least one compound of Claim 18 Claim 44.
- (Currently Amended) A method of treating metabolic disorder in a mammal, comprising the step of administering to the mammal in need thereof a therapeutically effective amount of at least one compound of Claim 18 Claim 44.
- 58. (Original) A method of Claim 57 wherein the mammal in need thereof is diagnosed as suffering from metabolic disorder.
- 59. (Canceled)
- 60. (Canceled)
- (Canceled)
- 62. (Canceled)
- 63. (Canceled)
- 64. (Canceled)
- 65. (Canceled)
- 66. (Canceled)
- 67. (Canceled)
- (New) A compound of that is {3-[2-Methyl-5-(4-trifluoromethyl-phenyl)-2H-pyrazol-3-ylmethoxy]-phenyl}-acetic acid or a pharmaceutically acceptable salt thereof.
- (New) A compound of that is {3-[2-Methyl-5-(4-trifluoromethyl-phenyl)-2H-pyrazol-3-ylmethoxyl-phenyl}-acetic acid.